Suleva Povea-Cabello

Suleva Povea-Cabello

Auto-generated profile, based on publicly available information

Suleva Povea-Cabello

Centro Andaluz de Biología del Desarrollo, ABD-CSIC-Universidad Pablo de Olavide, 41013 Sevilla, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PHPaula Cilleros Holgado
Paula Cilleros Holgado
DGDavid Gómez-Fernández
David Gómez-Fernández
RPRocío Piñero-Pérez
Rocío Piñero-Pérez
DRDiana Reche-López
Diana Reche-López
MÁMónica Álvarez-Córdoba
Mónica Álvarez-Córdoba
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
Mitochondrial dysfunction is a key pathological event in many diseases. Its role in energy production, calcium homeostasis, apoptosis regulation, and reactive oxygen species (ROS) balance render mitochondria essential for cell survival and fitness. However, there are no effective treatments for most primary and secondary mitochondrial diseases to this day. Therefore, new therapeutic approaches, such as the modulation of the mitochondrial unfolded protein response (mtUPR), are being explored. mtUPRs englobe several compensatory processes related to proteostasis and antioxidant system mechanisms. mtUPR activation, through an overcompensation for mild intracellular stress, promotes cell homeostasis and improves lifespan and disease alterations in biological models of mitochondrial dysfunction in age-related diseases, cardiopathies, metabolic disorders, and primary mitochondrial diseases. Although mtUPR activation is a promising therapeutic option for many pathological conditions, its activation could promote tumor progression in cancer patients, and its overactivation could lead to non-desired side effects, such as the increased heteroplasmy of mitochondrial DNA mutations. In this review, we present the most recent data about mtUPR modulation as a therapeutic approach, its role in diseases, and its potential negative consequences in specific pathological situations.

6 July 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
JSJuan Miguel Suárez-Rivero
Juan Miguel Suárez-Rivero
CPCarmen Julia Pastor-Maldonado
Carmen Julia Pastor-Maldonado
SPSuleva Povea-Cabello
Suleva Povea-Cabello
MÁMónica Álvarez-Córdoba
Mónica Álvarez-Córdoba
IVIrene Villalón-García
Irene Villalón-García
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
Mitochondrial dysfunction is a key hub that is common to many diseases. Mitochondria’s role in energy production, calcium homeostasis, and ROS balance makes them essential for cell survival and fitness. However, there are no effective treatments for most mitochondrial and related diseases to this day. Therefore, new therapeutic approaches, such as activation of the mitochondrial unfolded protein response (UPRmt), are being examined. UPRmt englobes several compensation processes related to proteostasis and antioxidant mechanisms. UPRmt activation, through an hormetic response, promotes cell homeostasis and improves lifespan and disease conditions in biological models of neurodegenerative diseases, cardiopathies, and mitochondrial diseases. Although UPRmt activation is a promising therapeutic option for many conditions, its overactivation could lead to non-desired side effects, such as increased heteroplasmy of mitochondrial DNA mutations or cancer progression in oncologic patients. In this review, we present the most recent UPRmt activation therapeutic strategies, UPRmt’s role in diseases, and its possible negative consequences in particular pathological conditions.

Verified
Journal Article
Open access
PDF file
ASAlejandra Suárez-Carrillo
Alejandra Suárez-Carrillo
MÁMónica Álvarez-Córdoba
Mónica Álvarez-Córdoba
ARAna Romero-González
Ana Romero-González
MTMarta Talaverón-Rey
Marta Talaverón-Rey
SPSuleva Povea-Cabello
Suleva Povea-Cabello
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
Neurodegeneration with brain iron accumulation (NBIA) is a group of rare neurogenetic disorders frequently associated with iron accumulation in the basal nuclei of the brain. Among NBIA subtypes, β-propeller protein-associated neurodegeneration (BPAN) is associated with mutations in the autophagy gene WDR45. The aim of this study was to demonstrate the autophagic defects and secondary pathological consequences in cellular models derived from two patients harboring WDR45 mutations. Both protein and mRNA expression levels of WDR45 were decreased in patient-derived fibroblasts. In addition, the increase of LC3B upon treatments with autophagy inducers or inhibitors was lower in mutant cells compared to control cells, suggesting decreased autophagosome formation and impaired autophagic flux. A transmission electron microscopy (TEM) analysis showed mitochondrial vacuolization associated with the accumulation of lipofuscin-like aggregates containing undegraded material. Autophagy dysregulation was also associated with iron accumulation and lipid peroxidation. In addition, mutant fibroblasts showed altered mitochondrial bioenergetics. Antioxidants such as pantothenate, vitamin E and α-lipoic prevented lipid peroxidation and iron accumulation. However, antioxidants were not able to correct the expression levels of WDR45, neither the autophagy defect nor cell bioenergetics. Our study demonstrated that WDR45 mutations in BPAN cellular models impaired autophagy, iron metabolism and cell bioenergetics. Antioxidants partially improved cell physiopathology; however, autophagy and cell bioenergetics remained affected.

26 September 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MÁMónica Álvarez-Córdoba
Mónica Álvarez-Córdoba
MTMarta Talaverón-Rey
Marta Talaverón-Rey
SPSuleva Povea-Cabello
Suleva Povea-Cabello
PHPaula Cilleros Holgado
Paula Cilleros Holgado
DGDavid Gómez-Fernández
David Gómez-Fernández
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
The term neurodegeneration with brain iron accumulation (NBIA) brings together a broad set of progressive and disabling neurological genetic disorders in which iron is deposited preferentially in certain areas of the brain. Among NBIA disorders, the most frequent subtype is pantothenate kinase-associated neurodegeneration (PKAN) caused by pathologic variants in the PANK2 gene codifying the enzyme pantothenate kinase 2 (PANK2). To date, there are no effective treatments to stop the progression of these diseases. This review discusses the utility of patient-derived cell models as a valuable tool for the identification of pharmacological or natural compounds for implementing polytarget precision medicine in PKAN. Recently, several studies have described that PKAN patient-derived fibroblasts present the main pathological features associated with the disease including intracellular iron overload. Interestingly, treatment of mutant cell cultures with various supplements such as pantothenate, pantethine, vitamin E, omega 3, α-lipoic acid L-carnitine or thiamine, improved all pathophysiological alterations in PKAN fibroblasts with residual expression of the PANK2 enzyme. The information provided by pharmacological screenings in patient-derived cellular models can help optimize therapeutic strategies in individual PKAN patients.

12 March 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
JSJuan Miguel Suárez-Rivero
Juan Miguel Suárez-Rivero
JLJuan López-Pérez
Juan López-Pérez
IMInés Muela-Zarzuela
Inés Muela-Zarzuela
CPCarmen Julia Pastor-Maldonado
Carmen Julia Pastor-Maldonado
PHPaula Cilleros Holgado
Paula Cilleros Holgado
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
Neurodegenerative diseases are characterized by the progressive loss of neurons, synapses, dendrites, and myelin in the central and/or peripheral nervous system. Actual therapeutic options for patients are scarce and merely palliative. Although they affect millions of patients worldwide, the molecular mechanisms underlying these conditions remain unclear. Mitochondrial dysfunction is generally found in neurodegenerative diseases and is believed to be involved in the pathomechanisms of these disorders. Therefore, therapies aiming to improve mitochondrial function are promising approaches for neurodegeneration. Although mitochondrial-targeted treatments are limited, new research findings have unraveled the therapeutic potential of several groups of antibiotics. These drugs possess pleiotropic effects beyond their anti-microbial activity, such as anti-inflammatory or mitochondrial enhancer function. In this review, we will discuss the controversial use of antibiotics as potential therapies in neurodegenerative diseases.

31 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
ASAlejandra Suárez-Carrillo
Alejandra Suárez-Carrillo
MÁMónica Álvarez-Córdoba
Mónica Álvarez-Córdoba
ARAna Romero-González
Ana Romero-González
MTMarta Talaverón-Rey
Marta Talaverón-Rey
SPSuleva Povea-Cabello
Suleva Povea-Cabello
José A Sanchez AlcazarJosé A Sanchez Alcazar
José A Sanchez Alcazar
Neurodegeneration with brain iron accumulation (NBIA) is a group of rare neurogenetic dis-orders frequently associated with iron accumulation in the basal nuclei of the brain. Among NBIA subtypes, β -propeller protein-associated neurodegeneration (BPAN) is associated with mutations in the autophagy gene WDR45. The aim of this study was to demonstrate autophagic defects and secondary pathological con-sequences in cellular models derived from two patient harboring WDR45 mutations. Both protein and mRNA expression levels of WDR45 were decreased in patient-derived fibro-blasts. In addition, the increase of LC3B upon treatments with autophagy inducers or inhibitors was lower in mutant cells compared to control cells, suggesting decreased autophagosome formation and impaired autophagic flux. Transmission electron microscopy (TEM) analysis showed mitochondrial vacuolization associated with accumulation of lipofuscin-like aggregates containing undegraded material. Autophagy dysregulation was also associated with iron ac-cumulation and lipid peroxidation. In addition, mutant fibroblasts showed altered mitochon-drial bioenergetics. Antioxidants such as pantothenate, vitamin E and α-lipoic prevented lipid peroxidation and iron accumulation. However, antioxidants were not able to correct the ex-pression levels of WDR45 neither the autophagy defect nor cell bioenergetics. Our study demonstrated that WDR45 mutations in BPAN cellular models impaired autophagy, iron metabolism and cell bioenergetics. Antioxidant partially improved cell physiopathology, however autophagy and cell bioenergetics remained affected.